- Home
- IMMR vs MNPR Comparison
IMMR vs MNPR Comparison
Compare IMMR & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMR
- MNPR
- Stock Information
- Founded
- IMMR 1993
- MNPR 2014
- Country
- IMMR United States
- MNPR United States
- Employees
- IMMR N/A
- MNPR N/A
- Industry
- IMMR Computer peripheral equipment
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- IMMR Technology
- MNPR Health Care
- Exchange
- IMMR Nasdaq
- MNPR Nasdaq
- Market Cap
- IMMR 237.6M
- MNPR 244.1M
- IPO Year
- IMMR 1999
- MNPR 2019
- Fundamental
- Price
- IMMR $7.94
- MNPR $37.66
- Analyst Decision
- IMMR Strong Buy
- MNPR Strong Buy
- Analyst Count
- IMMR 2
- MNPR 5
- Target Price
- IMMR $12.25
- MNPR $49.60
- AVG Volume (30 Days)
- IMMR 500.5K
- MNPR 34.7K
- Earning Date
- IMMR 03-12-2025
- MNPR 05-08-2025
- Dividend Yield
- IMMR 4.73%
- MNPR N/A
- EPS Growth
- IMMR 57.07
- MNPR N/A
- EPS
- IMMR 2.04
- MNPR N/A
- Revenue
- IMMR $163,133,000.00
- MNPR N/A
- Revenue This Year
- IMMR $988.71
- MNPR N/A
- Revenue Next Year
- IMMR $288.32
- MNPR N/A
- P/E Ratio
- IMMR $3.93
- MNPR N/A
- Revenue Growth
- IMMR 338.21
- MNPR N/A
- 52 Week Low
- IMMR $7.06
- MNPR $1.72
- 52 Week High
- IMMR $13.94
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- IMMR 48.99
- MNPR 53.00
- Support Level
- IMMR $7.35
- MNPR $34.13
- Resistance Level
- IMMR $7.65
- MNPR $47.83
- Average True Range (ATR)
- IMMR 0.26
- MNPR 4.94
- MACD
- IMMR 0.04
- MNPR 1.05
- Stochastic Oscillator
- IMMR 82.00
- MNPR 50.30
About IMMR Immersion Corporation
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.